Hill 2007.

Study characteristics
Methods	cRCT Unit of randomization: cluster of houses ICC: not reported Trial duration: 7 months (treatment period of 4 months)
Participants	Adults or children living in malaria‐endemic regions Non‐high risk population Endemic region for P vivax Participants not screened for hypnozoites
Interventions	Topical repellent: PMD: 30% + eucalyptus extract Controls: placebo lotion (0.1% clove oil used as placebo) Co‐interventions: LLINs Treatment arms: Intervention: 424 households (1967 individuals) Control: 436 households (2041 individuals)
Outcomes	Malaria infection incidence: new Plasmodium spp. infections confirmed through thick or thin blood smears, RDTs, or polymerase chain reaction (PCR) Incidence of recorded adverse events (including skin irritation, local pain, eye irritation, irritation of upper airways, nausea, vomiting, headaches, dizziness or confusion, allergic or anaphylactic reactions, and systemic toxicity). All‐cause fever Adherence to regular usage of the intervention (defined based on recommendations provided by researchers to participants of individual trials)
Notes	Carried out in Bolivia Funded by Gates Malaria Partnership grant from London School of Hygiene and Tropical Medicine